Jefferies Group Analysts Cut Earnings Estimates for UroGen Pharma (URGN)

UroGen Pharma (NASDAQ:URGN) – Research analysts at Jefferies Group cut their Q2 2018 earnings per share (EPS) estimates for UroGen Pharma in a research note issued on Wednesday, May 16th. Jefferies Group analyst M. Andrews now expects that the company will post earnings of ($0.90) per share for the quarter, down from their previous forecast of ($0.88). Jefferies Group has a “Buy” rating on the stock. Jefferies Group also issued estimates for UroGen Pharma’s Q3 2018 earnings at ($0.99) EPS, Q4 2018 earnings at ($1.18) EPS, FY2018 earnings at ($3.89) EPS, FY2019 earnings at ($4.57) EPS, FY2020 earnings at ($3.44) EPS, FY2021 earnings at ($2.29) EPS and FY2022 earnings at ($0.03) EPS.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Tuesday, May 15th. The company reported ($0.88) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.73) by ($0.15). The company had revenue of $0.48 million for the quarter.

A number of other research firms have also weighed in on URGN. Zacks Investment Research lowered shares of UroGen Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, May 8th. Oppenheimer set a $75.00 price objective on shares of UroGen Pharma and gave the stock a “buy” rating in a research note on Tuesday. Cowen reaffirmed a “buy” rating on shares of UroGen Pharma in a research note on Tuesday. UBS raised shares of UroGen Pharma from a “market perform” rating to an “outperform” rating in a research note on Wednesday, April 4th. Finally, Raymond James raised shares of UroGen Pharma from a “market perform” rating to an “outperform” rating in a research note on Wednesday, April 4th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $45.50.

NASDAQ:URGN opened at $62.04 on Friday. UroGen Pharma has a 1-year low of $61.05 and a 1-year high of $61.50.

A number of institutional investors have recently made changes to their positions in the business. Millennium Management LLC raised its holdings in UroGen Pharma by 1,285.4% in the first quarter. Millennium Management LLC now owns 159,113 shares of the company’s stock worth $7,906,000 after purchasing an additional 147,628 shares in the last quarter. DAFNA Capital Management LLC bought a new position in UroGen Pharma in the first quarter worth about $224,000. ETF Managers Group LLC raised its holdings in UroGen Pharma by 19.2% in the first quarter. ETF Managers Group LLC now owns 8,161 shares of the company’s stock worth $395,000 after purchasing an additional 1,316 shares in the last quarter. Barclays PLC bought a new position in UroGen Pharma in the first quarter worth about $1,242,000. Finally, UBS Group AG raised its holdings in UroGen Pharma by 31.5% in the first quarter. UBS Group AG now owns 3,611 shares of the company’s stock worth $180,000 after purchasing an additional 865 shares in the last quarter. Institutional investors and hedge funds own 53.00% of the company’s stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

Earnings History and Estimates for UroGen Pharma (NASDAQ:URGN)

Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Kratos Defense & Security Solutions  Given Average Recommendation of “Buy” by Brokerages
Kratos Defense & Security Solutions Given Average Recommendation of “Buy” by Brokerages
Stanley Black & Decker, Inc.  Receives Consensus Recommendation of “Buy” from Brokerages
Stanley Black & Decker, Inc. Receives Consensus Recommendation of “Buy” from Brokerages
Independence Contract  Receives $6.25 Average PT from Analysts
Independence Contract Receives $6.25 Average PT from Analysts
Gulf Resources  Getting Somewhat Favorable Media Coverage, Study Shows
Gulf Resources Getting Somewhat Favorable Media Coverage, Study Shows
Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Wayside Technology Group  Stock Price
Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Wayside Technology Group Stock Price
Brokerages Set Hunting plc  Price Target at $736.78
Brokerages Set Hunting plc Price Target at $736.78


Leave a Reply

© 2006-2018 Ticker Report. Google+.